IL2 and type 1 diabetes mellitus: Similar variability in Treg expansion and responsiveness may be present in humans, which highlights the need to identify biomarkers that can predict the response to mIL-2/CD25 as well as low-dose IL-2 treatment in T1D and other autoimmune diseases.